Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (DART)

June 09, 2017
1030826
Cancer, Cancer - Brain, Cancer - Breast, Cancer - Colon, Cancer - Esophogus, Cancer-Gynecologic, Cancer - Kidney, Cancer - Leukemia, Cancer - Lung, Cancer - Lymphoma, Cancer - Melanoma, Cancer - Multiple Myeloma, Cancer - Pancreatic, Cancer - Prostate
John McCann, MD
  • D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
  • Baystate Franklin Medical Center, 164 High Street, Greenfield, MA   
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Patients must have histologically confirmed rare cancer and/or cancer of unknown primary, that did not have a match to a molecularly-guided therapy on EAY131 “NCI-MATCH” protocol or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations per EAY131, “NCI-MATCH”.
Recruiting
Interventional (Clinical Trial), Non-Randomized
2
Katie Colbeck
(413) 794-9875